Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | EBP | Q15125 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9055095 | 0.87 | LTA4H (0.56) | LTA4HPSMB1PSMB5MCHR1PSMB2 | |
| SCHEMBL7529231 | 0.87 | EBP (0.57) | LTA4HPSMB1PSMB5MCHR1PSMB2 | |
| SCHEMBL3861283 | 0.85 | EBP (0.58) | LTA4HPSMB1PSMB5MCHR1HRH3 | |
| SCHEMBL7110375 | 0.83 | EBP (0.56) | LTA4HPSMB1PSMB5MCHR1HRH3 | |
| SCHEMBL7113155 | 0.83 | LTA4H (0.53) | LTA4HMCHR1EBPSIGMAR1ESR1 | |
| SCHEMBL8605470 | 0.82 | EBP (0.49) | LTA4HMCHR1HRH3EBPSIGMAR1 | |
| SCHEMBL7110875 | 0.82 | EBP (0.58) | LTA4HPSMB1PSMB5MCHR1HRH3 | |
| SCHEMBL7106662 | 0.81 | ESR1 (0.44) | LTA4HPSMB1PSMB5MCHR1PSMB2 | |
| SCHEMBL7111804 | 0.80 | EBP (0.54) | LTA4HPSMB1PSMB5MCHR1HRH3 | |
| SCHEMBL7106664 | 0.79 | LTA4H (0.41) | LTA4HPSMB1PSMB5MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | LTA4H 418/4885PSMB1 3230/4885PSMB5 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.